Journal Updates
eMediNexus Coverage from: 
Worse Prostate Cancer Outcomes With 5-Alpha-Reductase Inhibitors
eMediNexus,  12 May 2019
remove_red_eye 594 Views
#Hematology #Oncology #Pharmacist #Radiology #Urology

0 Read Comments                

Treatment with 5-alpha-reductase inhibitors (5-ARIs) is associated with worse mortality in prostate cancer, report findings from Veterans Affairs electronic health records.Dr. Brent S. Rose, from the University of California, San Diego in La Jolla, said, "5-ARIs, like finasteride and dutasteride, reduce the PSA by about 50%. It is very important to adjust the PSA for men on 5-ARIs to avoid the possibility of delayed prostate cancer detection."
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!